Visterra, Inc. Adds $8 Million, Ex-AMAG Pharmaceuticals, Inc. Execs, To Begin Clinical Push For Flu Antibody

Published: Dec 02, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Visterra has spent four years designing and fine-tuning an antibody that it thinks can combat all types of influenza. Now it’s pocketed some cash and filled out a revamped management team to take that drug into the clinic.

Cambridge, MA-based Visterra has added $8.1 million in venture dollars to its bank account, representing the third and final tranche from a $34.2 million Series A round that the company began raising last year.

Help employers find you! Check out all the jobs and post your resume.

Back to news